Clinical Trial

Superselective Renal Artery Embolization for Renal Angiomyolipoma

Study acronym: EAL
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy and safety of selective endovascular embolization in the treatment of renal angiomyolipoma (AML). Materials and Methods: A prospective analysis will be conducted on patients who undergo transcatheter renal artery embolization for renal angiomyolipoma. Inclusion criteria will be radiologically confirmed angiomyolipoma based on CT and/or MRI findings and the presence of clinical indications for embolization. The primary outcomes will include the assessment of changes in serum creatinine and hemoglobin levels post-procedure, technical success rates, and the incidence of any complications. Expected Results: Data on patient demographics, tumor characteristics, and procedural outcomes will be collected and analyzed. Conclusion: This study aims to determine whether selective endovascular embolization is a safe and effective treatment modality for renal angiomyolipoma, with the expectation of demonstrating a high rate of technical success while preserving renal function.
Trial Details
NCT Number NCT07538908
Lead Sponsor Botkin Hospital
Conditions Selective Endovascular Embolization of Kidney Artery
Enrollment 50 participants
Start Date 2026-04-06
Primary Completion 2027-04-10 (estimated)
Study Completion 2027-05-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-20